In this new commentary, @kangaslampi.bsky.social and I argue against viewing the psychedelic experience as a "biomarker" and challenge reductionistic drug-centered framings that obscure key psychosocial determinants of psychedelic therapy outcome, most notably psychotherapeutic processes.
LINK ⬇️
